Table 1 Characteristics of the eligible studies
Author | Publications years | Country | Population | Participants age (years) | Sample size transdermal estrogens combined with oral Medroxyprogesterone Acetate (MPA) /placebo | Duration | Baseline BMI (kg/m2) | Outcome | Intervention dose (mg) | Control group |
|---|---|---|---|---|---|---|---|---|---|---|
Ichikawa, A. | 2008 | Japan | Healthy postmenopausal women | 56.3 | 10/6 | 24 | 21 | TG, TC, LDL-C, HDL-C | Transdermal 17b-estradiol 36 mg/day + oral medroxyprogesterone acetate 2.5 mg daily for 12 days each month | No treatment |
Sumino, H. | 2006 | Japan | Postmenopausal women | 55.2 | 28/17 | 12 | 22.4 | TG, TC, HDL-C | Oral medroxyprogesterone acetate 2.5 mg/day for 12 days per month + transdermal 17b-estradiol 36mcg/day | No treatment |
Affinito, P. | 2001 | Italy | Postmenopausal hypertensive women | 53.5 | 25/27 | 6 | 25.7 | TG, TC, LDL-C, HDL-C | Oral medroxyprogesterone acetate 10 mg/day + transdermal estradiol 50 mg/day | Placebo |
West, S. G. | 2001 | USA | Postmenopausal women | 58 | 10/9 | 6 | 27 | TG, TC, LDL-C, HDL-C, | Oral medroxyprogesterone acetate 10 mg/day for 10 days each month + transdermal 17b-estradiol 50mcg/day | Placebo |
Os, I. | 2000 | Norway | Postmenopausal women | 63 | 60/58 | 12 | - | TG, TC, LDL-C, HDL-C, ApoA-I, ApoB | Oral medroxyprogesterone acetate 5 mg/day for 14 days every 3 months + daily transdermal 17b-estradiol 50mcg/day | Not specified |
Chmouliovsky, L. | 1999 | Switzerland | Overweight or obese postmenopausal women | 51 | 12/9 | 3 | 34 | TG, TC, LDL-C, HDL-C, ApoA-I, ApoB | Oral medroxyprogesterone acetate 5 mg/day + transdermal 17b-estradiol 50mcg/day | No treatment |
Pripp, U. | 1999 | Sweden | Postmenopausal women with coronary disease | 58.6 | 12/13 | 12 | - | TG, TC, LDL-C, HDL-C, | Oral medroxyprogesterone acetate 5 mg/day on days 19–28 of each 28-day cycle + transdermal 17b-estradiol 50mcg/day | Placebo |
Meschia, M. | 1998 | Italy | Naturally postmenopausal women | 51 | 12/19 | 12 | 24 | Lipoprotein (a) | Oral medroxyprogesterone acetate 10 mg/day for 12 days every 3 months + transdermal 17b-estradiol 50mcg/day | |
Perrone, G. | 1996 | Italy | Postmenopausal women | 51.1 | 12/19 | 12 | 24 | Lipoprotein (a) | Oral medroxyprogesterone acetate 10 mg/day for 12 days of each 28-day cycle + Transdermal 17b-estradiol 50mcg/day for 24.5 days of each 28-day cycle | |
Lemay, A. | 1995 | Canada | Healthy naturally postmenopausal women | 49.9 | 17/11 | 24 | 24.8 | TG, TC, ApoA-I, ApoB, | Oral medroxyprogesterone acetate 5 mg/day on days 14–25 + transdermal estradiol 50mcg/day on days 1–25 + no treatment on days 26–30 | No treatment |
Castelo-Branco, C. | 1993 | Spain | Surgically postmenopausal women post-hysterectomy | 48 | 20/19 | 12 | - | TG, TC, LDL-C, HDL-C, ApoA-I, ApoB | Oral medroxyprogesterone acetate 2.5 mg/day for the last 12 days of each cycle + transdermal 17b-estradiol 50mcg/day 24 days/month | No treatment |